Cyclophosphamide, Mitoxantrone, Fluorouracil versus Conventional CMF as Adjuvant Treatment in Node-Positive Breast Cancer Patients

Autor: Fountzilas, George, Polichronis, A., Katsohis, C., Gennatas, Constantinos, Toussis, D., Skarlos, Dimosthenis V., Kosmidis, Paraskevas A., Vassilaros, S., Semoglou, C., Giannakakis, T., Fahantidis, E., Klouvas, G. D., Tsavaris, N., Konstantaras, C., Makrantonakis, P., Kolotas, C., Zamboglou, N., Tsiliakos, S., Hainoglou, D., Mylonakis, N., Pavlidis, Nicholas
Přispěvatelé: Pavlidis, Nicholas [0000-0002-2195-9961]
Rok vydání: 1996
Předmět:
Oncology
Survival rate
Cancer Research
medicine.medical_treatment
Metastasis
Breast cancer
Controlled clinical trial
Tumor volume
Drug fatality
Relapse
Middle aged
Lymph node
Adjuvant
Priority journal
Gastrointestinal toxicity
Anemia
Nausea
General Medicine
Multicenter study
Clinical trial
medicine.anatomical_structure
Randomized controlled trial
Fluorouracil
Female
Menopause
Human
medicine.drug
Adult
Diarrhea
Node-positive
medicine.medical_specialty
Cyclophosphamide
Vomiting
Major clinical study
Follow-up studies
Bone marrow toxicity
Article
Gastrointestinal hemorrhage
Drug toxicity
Oral drug administration
Antineoplastic combined chemotherapy protocols
Internal medicine
Neurotoxicity
medicine
Carcinoma
Humans
Chemotherapy
Aged
Stomatitis
Mitoxantrone
business.industry
Recombinant granulocyte colony stimulating factor
Alopecia
Follow up
Leukopenia
medicine.disease
Thrombocytopenia
Cancer survival
Adjuvant chemotherapy
Liver necrosis
Methotrexate
Multivariate analysis
Remission induction
Intravenous drug administration
Heart infarction
Breast neoplasms
business
Controlled study
Constipation
Zdroj: Oncology (Switzerland)
ISSN: 1423-0232
0030-2414
DOI: 10.1159/000227550
Popis: 362 evaluable node-positive patients with stage II breast cancer were randomized, receiving either 6 cycles of conventional CMF or 6 cycles of the combination of cyclophosphamide (500 mg/m2), mitoxantrone (Novantrone 10 mg/ m2), and fluorouracil (500 mg/m2; CNF). After a median follow-up of 51 months, 64 (36%) patients relapsed in the CMF group and 60 (33%) in the CNF group (p = 0.8276). By Cox multivariate analysis, tumor size, menopausal status and number of involved nodes were retained as independently significant variables. Toxicities were remarkably similar in both groups. It appears that after a median follow-up of 51 months there is no significant difference in relapse-free survival between node-positive patients with breast cancer who received either 6 cycles of the conventional CMF or the CNF combination as adjuvant treatment. © 1996 S. Karger AG, Basel. 53 2 137 146
Databáze: OpenAIRE
Externí odkaz: